Company Profile

Previously a component part of the firm Integrated BioTherapeutics (IBT) in 2023 AbVacc, Inc. was spun off to focus on structure-guided design of vaccine and immunotherapeutic. is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases using structure-guided design. AbVacc’s pipeline includes promising product candidates for prevention and treatment of bacterial and viral infections. AbVacc’s bacterial program primary focus is on staphylococcal infections, by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. AbVacc’s S. aureus vaccine (IBT-V02), developed for prevention of recurrent skin and soft tissues infection, is expected to enter the clinic in 2023. AbVacc has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibodies against S. aureus virulence factors, currently under development for treatment of various S. aureus invasive diseases such as bacteremia and orthopedic infections. AbVacc’s antiviral pipeline includes unique Ebola and Marburg antibody therapeutics and vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for emerging viruses. Further, AbVacc has developed a novel antibody engineering platform technology for targeting anti-toxin antibodies to the surface of bacteria, integrating toxin neutralization with effector fun